scholarly journals Neuroimaging reward, craving, learning, and cognitive control in substance use disorders: review and implications for treatment

2019 ◽  
Vol 92 (1101) ◽  
pp. 20180942 ◽  
Author(s):  
Jody Tanabe ◽  
Michael Regner ◽  
Joseph Sakai ◽  
Diana Martinez ◽  
Joshua Gowin
Keyword(s):  
Substance Use ◽  
Cognitive Control ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Drugs Of Abuse ◽  
Brain Regions ◽  
Dopamine Neurons ◽  
Anterior Cingulate ◽  
Positron Emission ◽  
And Function

Substance use disorder is a leading causes of preventable disease and mortality. Drugs of abuse cause molecular and cellular changes in specific brain regions and these neuroplastic changes are thought to play a role in the transition to uncontrolled drug use. Neuroimaging has identified neural substrates associated with problematic substance use and may offer clues to reduce its burden on the patient and society. Here, we provide a narrative review of neuroimaging studies that have examined the structures and circuits associated with reward, cues and craving, learning, and cognitive control in substance use disorders. Most studies use advanced MRI or positron emission tomography (PET). Many studies have focused on the dopamine neurons of the ventral tegmental area, and the regions where these neurons terminate, such as the striatum and prefrontal cortex. Decreases in dopamine receptors and transmission have been found in chronic users of drugs, alcohol, and nicotine. Recent studies also show evidence of differences in structure and function in substance users relative to controls in brain regions involved in salience evaluation, such as the insula and anterior cingulate cortex. Balancing between reward-related bottom-up and cognitive-control-related top-down processes is discussed in the context of neuromodulation as a potential treatment. Finally, some of the challenges for understanding substance use disorder using neuroimaging methods are discussed.

scholarly journals Gray and white matter morphology in substance use disorders: A neuroimaging systematic review and meta-analysis

2020 ◽  
Author(s):  
Victor Pando-Naude ◽  
Sebastian Toxto ◽  
Sofia Fernandez-Lozano ◽  
E. Christine Parsons ◽  
Sarael Alcauter ◽  
...  
Keyword(s):  
Systematic Review ◽  
Substance Use ◽  
White Matter ◽  
Substance Use Disorders ◽  
Morphological Changes ◽  
Meta Analysis ◽  
Internal Capsule ◽  
Brain Regions ◽  
Anterior Cingulate ◽  
Consumption Pattern

AbstractSubstance use disorders (SUDs) are characterized by a compulsion to seek and consume one or more substances of abuse, with a perceived loss of control and negative emotional state. Repeated use of a substance results in synaptic and morphological changes, secondary to toxicity and SUD pathology in the dopamine striato-thalamo-cortical and limbic pathways. These neuroadaptations seem to vary between studies, which could be related to divergent effects of substances, consumption severity or other unknown factors. We therefore identified studies investigating the effects of SUDs using volumetric whole-brain voxel-based morphometry (VBM) in gray (GM) and white matter (WM). We performed a systematic review and meta-analysis of VBM studies using the anatomic likelihood estimation (ALE) method implemented in GingerALE (PROSPERO pre-registration CRD42017071222). Fifty studies met inclusion criteria and were included in the final quantitative meta-analysis, with a total of 538 foci, 88 experiments and 4370 participants. We found convergence and divergence in brain regions and volume effects (higher vs lower volume) in GM and WM depending on the severity of consumption pattern and type of substance. Convergent pathology was evident across substances in GM of the insula, anterior cingulate cortex, putamen, and thalamus, and in WM of the thalamic radiation and internal capsule bundle. Divergent pathology between occasional use (cortical pathology) and addiction (cortical-subcortical pathology) provides evidence of a possible top-down neuroadaptation. Our findings indicate distinctive brain morphometry alterations in SUDs, which may inform our understanding of disease progression and ultimately therapeutic approaches.

Neural Basis of Apathy

2021 ◽  
pp. 174-190
Author(s):  
Ingrid Agartz ◽  
Lynn Mørch-Johnsen
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Brain Regions ◽  
Anterior Cingulate ◽  
Resonance Imaging ◽  
Neural Basis ◽  
Positron Emission ◽  
White Matter Microstructure ◽  
Brain Structure And Function ◽  
And Function

This chapter introduces structural neuroimaging methods and presents results from brain imaging studies of the clinical apathy syndrome in neurodegenerative diseases such as Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, Huntington’s disease, and stroke, and also in schizophrenia, today considered a neurodevelopmental disease. The main method used has been magnetic resonance imaging, which also holds many innovative possibilities for future development. Scientific studies so far have pointed to structural differences in frontal, striatal, anterior cingulate, and parietal brain regions, and of white matter microstructure and connectivity changes as being involved in the apathy syndrome. No single circuit connected to apathy has so far been identified. Brain structure and function, studied at the systems network level, and integrative multimodal imaging approaches, which combine different high-resolution magnetic resonance imaging, magnetic resonance diffusion, and positron emission tomography techniques, can be helpful in resolving future questions.

scholarly journals Interactions of neuroimmune signaling and glutamate plasticity in addiction

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Cassandra D. Gipson ◽  
Scott Rawls ◽  
Michael D. Scofield ◽  
Benjamin M. Siemsen ◽  
Emma O. Bondy ◽  
...  
Keyword(s):  
Substance Use ◽  
Drug Use ◽  
Substance Use Disorders ◽  
Drugs Of Abuse ◽  
Treatment Strategies ◽  
Glutamate Signaling ◽  
Open Questions ◽  
Seeking Behavior ◽  
Glutamate System ◽  
Chronic Use

AbstractChronic use of drugs of abuse affects neuroimmune signaling; however, there are still many open questions regarding the interactions between neuroimmune mechanisms and substance use disorders (SUDs). Further, chronic use of drugs of abuse can induce glutamatergic changes in the brain, but the relationship between the glutamate system and neuroimmune signaling in addiction is not well understood. Therefore, the purpose of this review is to bring into focus the role of neuroimmune signaling and its interactions with the glutamate system following chronic drug use, and how this may guide pharmacotherapeutic treatment strategies for SUDs. In this review, we first describe neuroimmune mechanisms that may be linked to aberrant glutamate signaling in addiction. We focus specifically on the nuclear factor-kappa B (NF-κB) pathway, a potentially important neuroimmune mechanism that may be a key player in driving drug-seeking behavior. We highlight the importance of astroglial-microglial crosstalk, and how this interacts with known glutamatergic dysregulations in addiction. Then, we describe the importance of studying non-neuronal cells with unprecedented precision because understanding structure-function relationships in these cells is critical in understanding their role in addiction neurobiology. Here we propose a working model of neuroimmune-glutamate interactions that underlie drug use motivation, which we argue may aid strategies for small molecule drug development to treat substance use disorders. Together, the synthesis of this review shows that interactions between glutamate and neuroimmune signaling may play an important and understudied role in addiction processes and may be critical in developing more efficacious pharmacotherapies to treat SUDs.

scholarly journals Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [11C]raclopride study in humans

2011 ◽  
Vol 199 (5) ◽  
pp. 391-397 ◽  
Author(s):  
Sylvia M. L. Cox ◽  
Chawki Benkelfat ◽  
Alain Dagher ◽  
J. Scott Delaney ◽  
France Durand ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Striatal Dopamine ◽  
Emission Tomography ◽  
Acute Tryptophan Depletion ◽  
Tryptophan Depletion ◽  
Comorbid Conditions ◽  
Drug Craving ◽  
Positron Emission ◽  
Wide Range

BackgroundLow serotonin transmission is thought to increase susceptibility to a wide range of substance use disorders and impulsive traits.AimsTo investigate the effects of lowered serotonin on cocaine-induced (1.0 mg/kg cocaine, self-administered intranasally) dopamine responses and drug craving.MethodIn non-dependent cocaine users, serotonin transmission was reduced using the acute tryptophan depletion method. Striatal dopamine responses were measured using positron emission tomography with [11C]raclopride.ResultsAcute tryptophan depletion increased drug craving and striatal dopamine responses to cocaine. These acute tryptophan depletion-induced increases did not occur in the absence of cocaine.ConclusionsThe results suggest that low serotonin transmission can increase dopaminergic and appetitive responses to cocaine. These findings might identify a mechanism by which individuals with low serotonin are at elevated risk for both substance use disorders and comorbid conditions.

scholarly journals Effects of an Adenosine A2A Receptor Antagonist on Striatal Dopamine D2-Type Receptor Availability: A Randomized Control Study Using Positron Emission Tomography

2021 ◽  
Vol 15 ◽  
Author(s):  
Kyoji Okita ◽  
Koichi Kato ◽  
Yoko Shigemoto ◽  
Noriko Sato ◽  
Toshihiko Matsumoto ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Substance Use ◽  
Receptor Antagonist ◽  
Substance Use Disorders ◽  
Emission Tomography ◽  
Binding Potential ◽  
Dopamine D2 ◽  
Positron Emission ◽  
A2a Receptor ◽  
Type Receptor

Introduction: Altered dopaminergic neurotransmission, especially in the functioning of dopamine D2-type receptors, is considered central to the etiology of a variety of neuropsychiatric disorders. In particular, individuals with substance use disorders have been consistently observed to exhibit lower D2-type receptor availability (quantified as binding potential; BPND) using positron emission tomography (PET). Upregulation of D2-type receptor density thus may therefore provide a therapeutic effect for substance use disorders. Importantly, in vitro studies reveal that D2 receptors coexist with adenosine 2A (A2A) receptors to form the highest density of heteromers in the whole striatum, and there is a functional interaction between these two receptors. As such, blockade of A2A receptor’s function may prevent D2 receptor downregulation, yet no study has currently examined this hypothesis in humans.Methods and Analysis: This double-blind, randomized controlled trial aims to evaluate the effect of the A2A receptor antagonist istradefylline (compared to placebo) on both dopamine D2-type receptor availability in the human brain and on neuropsychological measurements of impulsivity. It is hypothesized that istradefylline will both increase striatal D2-type BPND and improve control of impulsivity more than placebo. Forty healthy participants, aged 20–65 with no history of psychiatric or neurological disorders, will be recruited and randomized into two groups and will undergo [11C]raclopride PET, once before and once after administration of either 40 mg/day istradefylline or placebo for 2 weeks. Neuropsychological measurements will be administered on the same days of the PET scans.Ethics and Dissemination: The study protocol was approved by the Certified Review Boards (CRB) of National Center of Neurology and Psychiatry (CR18-011) and prospectively registered with the Japan Registry of Clinical Trials (jRCTs031180131; https://jrct.niph.go.jp/latest-detail/jRCTs031180131). The findings of this study will be disseminated through peer reviewed scientific journals and conferences.Clinical Trial Registration:www.ClinicalTrials.gov, identifier jRCTs031180131.

scholarly journals Co -occurring Mental Disorders among In-patients in a Substance use Disorder Treatment Center in Plateau State, Nigeria

2020 ◽  
Vol 3 (1) ◽  
pp. 223-229
Author(s):  
D M Makput
Keyword(s):  
Substance Use ◽  
Drug Abuse ◽  
Mental Disorders ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Addiction Treatment ◽  
Treatment Center ◽  
Post Traumatic Stress ◽  
Functional Abnormality ◽  
Plateau State

Patients with psychoactive substance use disorders (SUD) often have co- occurring medical and mental disorders. This occurs as a result of a number of factors, for instance, drug abuse may facilitate the full expression of a latent psychiatric disorder; mental disorder may lead to SUD (drugs used for self- medication; or both SUD and mental disorders are caused by the same underlying brain deficit such as genetic vulnerability, neurotransmitter abnormality, structural or functional abnormality, and so on. After obtaining ethical clearance, the case notes of all patients who were admitted in the Centre for Addiction Treatment and Research, (CATR) Vom, Plateau state throughout the first quarter of year 2019 were traced. A systematic random sample of every third consecutive patient was selected beginning with the first patient admitted and relevant data were collected and analyzed. A total of fourty- eight (48) in-patients were analyzed. Ninety -four percent (94%) of the patients were males, the mean age of 23.6 + 5 years with 46% being below 25 years of age. Fourty-six percent (46%) had cannabis as their primary drug followed by alcohol (32%) and opioids (28%). Only 1 % had a history of injecting drug use. Twenty-nine percent (29%) of the SUD patients had co-occurring depression, nine percent (8%) had anxiety disorder, and five percent (4%) had Post Traumatic Stress Disorder (PTSD) in addition to their substance use disorder. In line with sustainable development goals (SDG) goal 3.5 which seeks to “strengthen prevention and treatment of substance abuse including narcotics drug abuse and harmful use of alcohol”; identifying co-occurring mental disorders among patients with substance use disorders is one way of moving closer towards achieving this SDG.

scholarly journals Recovery-informed Theory: Situating the Subjective in the Science of Substance Use Disorder Recovery

2019 ◽  
Vol 1 (3) ◽  
pp. 1-15 ◽  
Author(s):  
Austin M Brown ◽  
Robert D Ashford
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Systems Of Care ◽  
Grand Theory ◽  
Recovery Strategies ◽  
Recovery Capital ◽  
New Ideas

As recovery from substance use disorder becomes more than a mere quantifiable outcome, there exists a need to discuss and propose the underlying theoretical constructs that ultimately describe and identify the science of recovery. In this abstract undertaking, we propose an initial formulation of a grand theory of recovery science, built upon the seminal theories of recovery capital, recovery-oriented systems of care, and socioecological theory. This grand theory - labeled recovery-informed theory (RIT) - states that successful long-term recovery is self-evident and is a fundamentally emancipatory set of processes. This paper will discuss, analyze, and explore this theory as it is situated within the larger substance use, misuse, and disorder contexts. The uses, implications, and benefits of RIT as an organizing point of inquiry for recovery science are also discussed. By promoting the role of subjective recovery experience in the formulation of the study of recovery, it may be possible to summon new ideas, metrics, and strategies that can directly address substance use disorders in society. Adopting a recovery-informed understanding as follows from this grand theory may allow individual recovery and wellness trajectories to be explored, adapted, and modified to exemplify person-centered and individualized recovery strategies.

Outline of This Treatment Program

2014 ◽  
pp. 25-42
Author(s):  
Sudie E. Back ◽  
Edna B. Foa ◽  
Therese K. Killeen ◽  
Katherine L. Mills ◽  
Maree Teesson ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Treatment Program ◽  
Post Traumatic Stress Disorder ◽  
Traumatic Stress ◽  
Post Traumatic Stress ◽  
Post Traumatic ◽  
Focus Questions

This chapter provides the therapist with an outline of the COPE treatment and components of each session (e.g. check-in, review homework, post-traumatic stress disorder [PTSD] focus, substance use disorder focus). Questions regarding who can deliver the therapy are addressed, as well as questions regarding the role of medications. Finally, special considerations for delivering treatment to patients with PTSD and comorbid substance use disorders are reviewed for the therapist.

Recognizing Consequences of Your Substance Use

2019 ◽  
pp. 19-22
Author(s):  
Dennis C. Daley ◽  
Antoine Douaihy
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Economic Problems ◽  
The People ◽  
Life Threatening

Substance use can contribute directly and indirectly to problems in any area of life. Substance use disorders raise the risk of medical, spiritual, psychological, psychiatric, family, and economic problems. Problems may range in severity from mild to life-threatening. Sometimes the effects are subtle or hidden. The goals of this chapter are for the client to understand the consequences of their substance use and its effect on the people closest to them and to identify problems caused by the client’s substance use disorder.

Sign in / Sign up

Export Citation Format

Share Document